AiCure and IMA partner for clinical trial recruitment optimisation
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

AiCure and IMA partner for clinical trial recruitment optimisation

16 Mar 2021

US-based data analytics company AiCure and The IMA Group have announced a partnership for the optimisation of clinical trial recruitment and patient engagement.

AiCure and IMA partner for clinical trial recruitment optimisation
The IMA Group will equip patients with AiCure’s patient engagement solution to observe health management outside of a study setting, helping advance recruitment for future clinical trials. Credit: AiCure.

US-based data analytics company AiCure and The IMA Group have formed a partnership to optimise clinical trial recruitment and patient engagement.

This year-long collaboration aims to understand patient behaviour and drug compliance outside a clinical trial.

The IMA Group’s division IMA Clinical Research will equip patients with AiCure’s patient engagement solution ‘Patient Connect’ to study health management outside a trial. This solution is intended to help patients manage their treatment at home.

Sponsors will get access to a diverse pool of patients with known adherence patterns across therapeutic areas that could be recruited for upcoming trials.

AiCure CEO Dr Ed Ikeguchi said: “The success of a clinical trial depends on the quality of its data, which often comes down to how likely a patient is to comply with treatment protocols.

“Understanding that risk and how a patient manages their health in a non-trial setting before recruiting them can make a critical difference in a trial setting.”

Through its partnership with AiCure, the company will start patient engagement and compliance measurement to medications outside of a study setting.

The partnership will also assess compliance to treatment across various conditions, ranging from pain to cardiovascular conditions, CNS diseases, and diabetes.

During a 30-day programme, patients will use AiCure’s solution through their smartphone each time they take a dose.

The solution confirms adherent dosing behavior in a HIPAA compliant manner, using computer vision and AI.

Patient Connect can identify subtle changes in a patient’s condition by aggregating ePRO and digital biomarker data.

Patients will also be able to connect directly to a clinician for further support.

The data collected can be fed into AiCure’s predictive analytics engine, while will enable future sponsors to gain insights about dosing behaviour across various disease states.